INBRX-106

Drug identity checked against registry records

Also recorded as Hexavalent OX40 agonist antibody; Ordastobart

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)NCT06295731INBXPhase 2, Phase 3Recruiting2029-12Estimated

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.